CSI Market
Sign In | Register

Ionis Pharmaceuticals Inc (IONS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access IONS Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Ionis Pharmaceuticals Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-207.17
Depreciation & amortization6.73
Amortization of Other Assets5.51
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Finite-lived0.48
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories24.63
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation88.87
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Amortization Of Patents-
Amortization Of Licenses-
Investment Income Net Amortization Of Discount And Premium-
Income Losses Related To Patents And Property Plant And Equipment-
Amortization Of Debt Discount Premium One-
Amortization Of Debt Discount Premium Two-
Gain Loss On Available For Sale Equity Securities Significant Investment-
Gain Loss On Available For Sale Equity Securities Excluding Significant Investment-
Deferred Income Tax Expense Benefit Unrealized Gains On Securities-
Increase Decrease In Contracts Receivable Net-
Increase Decrease In Contract With Customer Asset-7.63
Royalty Payments-11.69
Operating Lease Right Of Use Asset Amortization Expense3.49
Increase Decrease In Contract With Customer Liability-20.82
Income taxes0.00
Realized Investment Gains (Losses), Total12.40
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities0.00
Increase (Decrease) in Accounts Payable18.58
Increase (Decrease) in Other Employee Related Liabilities-65.94
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital51.12
Other Noncash Income (Expense)0.00
Other net9.53
Payments for (Proceeds from) Other Operating Activities-172.03
Discontinued operations0.00
Net Cash flow from Operating Activities-227.29
Investing Activities
Capital Expenditures-41.48
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities1,114.81
Payments to Acquire Available-for-sale Securities, Debt-513.01
Real Estate Investments0.00
Cash Flow Impact Upon Adoption Of New Accounting Standard-
Payments To Acquire Licenses And Other Assets-
Purchases Of Strategic Investments-
Proceeds From The Sale Of Strategic Investments-
Payments To Acquire Equity Securities Fv Ni-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities560.32
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-432.60
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock77.56
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Equipment Financing Arrangement-
Payment To Settle Financing Liability For Leased Facility-
Non Cash Capital And Patent Expenditures-
Unpaid Deferred Offering Costs-
Early Repayment Of Convertible Debt-
Royalty Monetization Issuance Costs-
Proceeds From Sale Of Future Royalties-
Payments For Transaction Costs Related To Sale Of Future Royalties-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-355.04
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-268.77
Total Cash Flow-22.20
4 historic quarters locked

Sign in to unlock the full Ionis Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Ionis Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: July 29, 2026
  • Source: form10q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000874015-26-000251

Figures are derived from filed reports and may be restated. Historical data is subject to revision.